RonanRx, Inc. dba RonanRx – FDA Warning Letter, Sep 1, 2026

On October 30, 2026, the FDA issued a warning letter to RonanRx, Inc. (dba RonanRx) following a September 2026 review of the company"s website and social media presence. The agency identified significant violations involving the promotion of compounded semaglutide and tirzepatide products, which are often used for weight management. The FDA found that RonanRx engaged in misbranding by making false and misleading claims. Specifically, the company’s marketing suggested that its compounded medications were FDA-approved or extensively studied for safety and efficacy, despite the fact that compounded drugs do not undergo the standard FDA approval process. Furthermore, the company falsely claimed its products were "American made" and "farm-to-table," while federal records indicated the active pharmaceutical ingredients were not produced by registered domestic manufacturers. Labeling also incorrectly implied that RonanRx was the actual compounder of the drugs. These activities violate the Federal Food, Drug, and Cosmetic Act regarding the introduction of misbranded drugs into interstate commerce. RonanRx is required to respond within 15 working days, providing a detailed plan to correct these violations, identifying the actual producers of the drugs, and removing all misleading promotional materials to ensure future compliance with federal law.